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Abstract
Background: Community-acquired pneumonia (CAP) mortality exceeds 20 % in critical care patients despite
appropriate antibiotic therapy. Regional tissue oxygen saturation index (rSO2) measured with near-infrared
spectroscopy (NIRS) might facilitate early detection for patients at risk of serious complications. Our objectives
were to determine the relationship between early determination of rSO2 and mortality and to compare
discrimination power for mortality of rSO2 and other resuscitation variables in critically ill CAP patients.
Methods: This is a prospective observational study. Patients with CAP were enrolled within 6 h to intensive
care admission. Demographics and clinical variables were recorded. rSO2 was determined using NIRS in brachioradialis
muscle. All variables were determined at baseline and 24 h after admission.
Results: Forty patients were enrolled. Fourteen patients (35 %) had a baseline rSO2 < 60 % and 7 of them died (50 %).
Only 1 of 26 (3.8 %) patients with rSO2≥ 60 % died (p = 0.007). The area under ROC curve (AUROC) showed consistent
mortality discrimination at baseline (0.84, p = 0.03) and at 24 h (0.86, p = 0.006) for rSO2 values. Cox regression analysis
showed that “low” rSO2 at ICU admission (hazard ratio (HR) = 8.99; 95 % confidence interval (CI) 1.05–76.8; p = 0.045)
and “low” rSO2 at 24 h (HR = 13.18; 95 % CI 1.52–113.6; p = 0.019) were variables independently associated
with mortality. In contrast, other variables such as Acute Physiology and Chronic Health Evaluation (APACHE II) score
(HR = 1.09; 95 % CI 0.99–1.19; p = 0.052) were not associated with mortality.
Conclusions: Our findings suggest that forearm skeletal muscle rSO2 differs in patients with severe CAP according to
outcome and might be an early prognosis tool.
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Background
Community-acquired pneumonia (CAP) is an important
cause of morbidity, mortality and increased health-care
costs [1–3]. CAP is considered severe when admission
to the intensive care unit (ICU) is needed due to respira-
tory distress or septic shock and occurs in about 9–16 %
of hospitalized patients [4, 5]. In patients with severe
CAP, mortality rates ranged from 20 to 50 % according
to the presence of shock, the accuracy of process of care,
need for mechanical ventilation and underlying diseases
[1–9]. Prompt initiation of appropriate antibiotic therapy
and adequate resuscitation are recommended as it po-
tentially benefits patients’ prognosis [10, 11] However,
the mortality rate in immunocompetent patients admit-
ted to the ICU by CAP with appropriate antibiotic
therapy exceeds 20 % [3] suggesting that antibiotics
alone are not enough.
Microvascular alterations are recognized as a key char-
acteristic contributing to organ dysfunction and death in
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patients with sepsis [12–14]. Microvascular dysfunction
leads to reduced oxygen delivery and extraction, causing
heterogeneous and deficient tissue oxygenation, which is
associated with adverse clinical outcome.
Global hemodynamic and metabolic parameters are
used in current practice as resuscitation endpoints in se-
vere sepsis and septic shock [11]. However, normalization
of relevant variables such as mean arterial pressure
(MAP), central venous pressure (CVP), cardiac output
(CO) or serum lactate is not enough to define oxygenation
status and aerobic metabolism in peripheral tissues
[15–21] Increasing evidence suggests that regional
oxygen saturation index (rSO2) determined by near-
infrared spectroscopy (NIRS) might allow early detec-
tion of patients at risk of serious complications and
have prognostic implications [17, 18].
We hypothesized that brachioradialis muscle rSO2
could reflect the prognosis in patients with severe CAP.
Methods
Ethics, consent and permissions
The study was performed from January 2011 to December
2013 in a 30-bed medical-surgical ICU in a tertiary univer-
sity hospital. It was a prospective single centre, observa-
tional clinical study. The investigation was conducted
according to the principles outlined in the Declaration of
Helsinki. The study protocol was approved by the Joan
XXIII University Hospital Ethics Committee (MICRO2
20/2010), and informed consent was given by each patient
or their next of kin.
Study population
Consecutive adult patients with severe CAP requiring
admission to the ICU were enrolled. The diagnosis of
CAP was based on (a) the detection of a new and persist-
ent pulmonary infiltrate for which there is no other ex-
planation and at least two of the following clinical criteria:
(1) fever or hypothermia (temperature >38 or < 35.5 °C);
(2) leucopenia or leukocytosis (white blood cells ≤4x109/L−1
or ≥12 x109/ L−1) or (3) purulent respiratory secretions
and (b) acquisition of the infection outside a hospital,
long-term care facility or nursing home [22]. Patients were
admitted to the ICU if they presented at least one of
following criteria: signs and symptoms of respiratory fail-
ure (respiratory rate >30/min, accessory musculature
utilization, low SpO2 despite oxygen supplementation),
needed mechanical ventilation, or presented with criteria
of severe sepsis or septic shock. All patients admitted to
the ICU were considered to present severe CAP. We
decided to include only CAP patients in order to obtain a
homogeneous population of patients to increase the
internal validity of the study.
We excluded (a) patients <18 years old; (b) immuno-
suppression, defined as any primary immunodeficiency
or immunodeficiency secondary to HIV infection, active
malignancies, radiation treatment or use of cytotoxic drugs,
or steroids drugs (daily doses >40 mg of prednisolone or
equivalent for >2 weeks), immunological disease, solid
organ transplant and haematological disease; (c) hospital-
acquired pneumonia or health-care-associated pneumonia;
(d) morbid obesity (body mass index >30 kg/m2); (e)
clinical edema and (f ) injuries in forearms.
Study protocol
Patients were enrolled at ICU admission. Information
collected included demographic characteristics, Acute
Physiology and Chronic Health Evaluation (APACHE II)
score [23], Sequential Organ Failure Assessment (SOFA)
score [24] and global hemodynamic variables as heart
rate (HR), CVP, MAP and mixed venous oxygen saturation
(SvO2) when possible. Serum lactate and base deficit were
obtained as markers of resuscitation and were determined
at baseline and 24 h after ICU admission. The patients
were treated with fluid administration and vasopressor
therapy as required, according to the local guidelines
adapted from Surviving Sepsis Campaign guidelines [11].
Patients were monitored at ICU admission using a central
venous pressure (CVP) or echocardiography depending on
the attending physician’s decision. Resuscitation was
guided using CVP or echocardiography-derived parame-
ters, and if advanced hemodynamic monitoring was
needed, a pulmonary artery catheter was inserted. Fluid
resuscitation was administered by fluid bolus challenge
with crystalloids and/or artificial colloids, targeting a CVP
8–12 mmHg or if the patient showed >20 % collapsibility
of the inferior cava vein during inspiration in ventilated
patients (>50 % collapsibility in patients in spontaneous
ventilation). When fluid administration was not enough to
improve the patient’s hemodynamic status, the vasopressor
agent of choice was norepinephrine titrated to the 2 μg/kg/
min maximum dose to maintain the MAP >65 mmHg.
Shock was defined as the need for vasopressors for >4 h
after fluid replacement [8]. In accordance with our local
guidelines, all patients were treated with antibiotic combin-
ation therapy (ceftriaxone plus macrolide) for CAP. All
patients were evaluated during the first 24 h after ICU ad-
mission. We recorded if, at the time of admission, patients
met major criteria according to the American Thoracic
Society (need of mechanical ventilation or shock) [25].
Treatment was administered by an independent physician
team that was blinded for rSO2 values. Patients were
followed up for outcome data until ICU discharge or ICU
death.
Regional oxygen saturation index (rSO2) measurements
A probe somasensor was placed on the medial forearm
(brachioradialis muscle) at a distance 5 cm distal to the
elbow of each subject to obtain skeletal muscle rSO2
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measurement as described elsewhere [17, 18]. Measure-
ments were obtained using a commercially available
NIRS spectrometry system INVOS 5100C oximeter
(Somanetics Corporation, Troy. MI, USA), with a non-
sterile and disposable skin surface probe. This system
functions with two NIRS probes, one with 30-mm and
the other with 40-mm spacing between NIR light send
and receive optical fibre tips. The 30-mm signal is sub-
tracted from the 40-mm signal, with the intention of
subtracting the skin and subcutaneous fat layer artefact
from the underlying skeletal muscle. For all patients,
rSO2 was recorded at baseline and at 24 h. NIRS data
was not used in patients’ management. According to our
previous data [17, 18], we defined a threshold in <60 %
as a “low rSO2”.
Primary and secondary outcomes
The main objective of this study was to determine the re-
lationship between early brachioradialis rSO2 values and
mortality. Secondary outcomes were to compare the dis-
crimination power for ICU mortality of brachioradialis
rSO2 with standard variables of resuscitation and to evalu-
ate the patients’ evolution according to the variation of
rSO2 in the first 24 h.
Statistical analysis
Discrete variables are expressed as counts (percentage)
and continuous variables as means and standard devia-
tions or medians within the 25th to 75th interquartile
range (IQR). For demographic and clinical characteris-
tics of the patients, differences between groups were
assessed using the chi-square test and Fisher’s exact test
for categorical variables and the Student t test, Mann-
Whitney U test or Kruskal-Wallis test for continuous
variables. Pearson’s correlation coefficient was used to
assess the association between continuous variables. The
concordance of the values obtained for different correla-
tions was assessed using the intraclass correlation coeffi-
cient (ICC), based on the model of analysis of variance
for repeated measures by the process reliability. Cumula-
tive survival was assessed using Kaplan-Meier plot. Cox
regression analysis was performed to determine which
variables were independently associated with mortality.
We included the variables that showed a significant
association with mortality in the univariate analysis as
covariables in the model: APACHE II score, rSO2 value,
presence of shock and need for mechanical ventilation.
The predictive values for skeletal rSO2 and the other
variables of resuscitation were calculated using a receiver
operator characteristic (ROC) curve, and the area under
ROC curve (AUROC) was computed. The ROC graph
was a plot of all the sensibility/specificity pairs resulting
from continuously varying the decision threshold over
the entire range of results observed. Data analysis was
made using SPSS for Windows 13.0 (SPSS, Chicago, IL,
USA). For all analyses, p < 0.05 was considered significant.
Results
Forty patients with severe CAP were enrolled. Median
APACHE II score and SOFA score were 17.0 (IQR =
12–21) and 4.0 (IQR = 3–5) points respectively, with
an overall ICU mortality of 20 %. Additional demo-
graphics, baseline and 24 h hemodynamic and bio-
chemical data with simultaneous measurements of
skeletal muscle rSO2 are shown in Table 1.
Non-survivors had higher APACHE II score, greater
need for invasive mechanical ventilation and higher
frequency of septic shock compared to survivors. All
non-survivors had major ATS criteria.
We found no significant differences in hemodynamic
and biochemical data according to evolution. Brachiora-
dialis rSO2 was the only variable associated with mortality
at admission and at 24 h. Twenty-two patients (55 %) had
shock at admission. Shock patients had lower rSO2 at
baseline (59 % [SD 10.7] vs. 67 % [SD 8.9], p < 0.001) and
at 24 h (61 % [SD 11.5] vs. 72 % [SD 10.6], p < 0.009) than
patients without shock. However, we observed no signifi-
cant correlation neither between MAP and rSO2 at base-
line (r = 0.19, p = 0.90) and at 24 h (r = 0.07, p = 0.68) nor
with rSO2 and norepinephrine doses at baseline (r = 0.11,
p = 0.67) and at 24 h (r = −0.46, p = 0.06). In contrast,
serum lactate at 24 h showed a weak but significant
correlation with rSO2 at 24 h (r = 0.66, p = 0.001). In all
cases, the concordance was poor and it was not signifi-
cant. A central venous catheter for CVP measurement
was inserted in 22 patients, the rest of them were moni-
tored using echocardiography-derived parameters. SvO2
was available in only 11 (27, 5 %) patients. SvO2 values
were 76 and 70 % at baseline and at 24 h, respectively. We
observed no significant correlation between rSO2 and
SvO2 at any time of the study (data not shown).
Patients with baseline “low rSO2” had a significantly
higher ICU mortality rate than patients with rSO2 ≥ 60 %
(Fig. 1). Fourteen patients (35 %) had a baseline skeletal
muscle rSO2 < 60 %, and seven of them (50 %) died. In
contrast, only one patient (3.8 %) with rSO2 ≥ 60 % died
(p = 0.001). This represents more than sixfold increase in
the risk of death (OR 6, 25; 95 % CI 1.0–39.4) despite
similar levels of severity of illness and resuscitation vari-
ables (Table 2). We differentiate patients according to
variation of the value of rSO2 from ICU admission to 24 h
later. Three types of trends were observed: (1) a group of
patients which showed no improvement or a decrease in
rSO2 value (no responders); (2) other group which showed
an improvement in rSO2 value to reach rSO2 of >60 % at
24 h (responders); and (3) a group of patients in which the
rSO2 value improved but did not reach >60 % at 24 h
(partially responders). We observed different outcomes
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Table 1 Clinical characteristics, hemodynamic variables and biochemical data with simultaneous measurements of skeletal muscle
rSO2 of 40 patients included
Variable Overall (n = 40) Survivors (n = 32) Non-survivors (n = 8)
Demographic data
Age (years), mean (SD) 55.5 (15.9) 53 (16.4) 65 (9.8)*
Male, n (%) 27 (67.5) 21 (65.6) 6 (75.0)
Severity of illness
APACHE II score at day 1, median (IQR 25–75) 17 (12–21) 16 (12–20) 22 (18–34)**
SOFA score at day 1, median (IQR 25–75) 4 (3–5) 4 (3–5) 4 (3–8)
Major ATS criteria, median (IQR 25–75) 28 (70) 20 (62.5) 8 (100)**
Invasive mechanical ventilation, n (%) 21 (52.5) 13 (40.6) 8 (100)***
Severe sepsis, n (%) 18 (44.5) 17 (53.1) 1 (12.5)
Septic shock, n (%) 22 (55.5) 15 (46.9) 7 (87.5)*
Mean comorbidities, n (%)
Tobacco use 3 (8.6) 3 (10.7) 0
Chronic obstructive pulmonary disease 12 (33.3) 10 (34.3) 2 (28.6)
Cardiac disease 8 (20) 6 (18.7) 2 (28.6)
Diabetes mellitus 7 (20) 5 (17.9) 2 (28.6)
Severe liver disease 1 (2.9) 0 1 (14.3)
Hemodynamic data, median (IQR 25–75)
Heart rate, b/min 105 (86–114) 105 (87–114) 105 (85–113)
Heart rate at 24 h 90 (77–100) 92 (79–103) 85 (70–99)
Mean arterial pressure, mmHg 79 (71–94) 78 (72–98) 80 (69–88)
Mean arterial pressure at 24 h 79 (70–93) 76 (70–96) 79 (71–90)
Central venous pressure, mmHg 11 (9–15) 11 (8–15) 11 (10–14)
Central venous pressure at 24 h 13 (13–16) 11 (7–16) 14 (12–15)
Mixed venous oxygen saturation, %a 76 (70–79) 76 (69–79) 74 (74)
Mixed venous oxygen saturation at 24 ha 70 (68–83) 70 (68–80) 80 (70–91)
Biochemical data, mean (SD)
Baseline serum lactate, mM/L 3.0 (3.1) 2.5 (1.6) 4.8 (6.1)
Serum lactate at 24 h 2.0 (2.2) 1.4 (0.6) 3.9 (4.0)
Baseline base deficit −3.5 (5.2) −3.6 (5.4) −2.7 (4.3)
Base deficit at 24 h −2.3 (4.1) −1.9 (4.1) −3.4 (4.2)
Baseline haemoglobin levels, mg % 11.9 (1.8) 12.1 (1.9) 11.2 (1.1)
Haemoglobin levels at 24 h 10.6 (1.7) 10.6 (1.9) 10.4 (1.1)
Baseline serum glucose, mg % 166 (74.7) 158 (75.3) 197 (66.8)
Serum glucose at 24 h 152 (75.6) 144 (79.4) 177 (58.7)
Baseline arterial pH 7.34 (0.1) 7.40 (0.1) 7.34 (0.3)
Arterial pH at 24 h 7.36 (0.07) 7.30 (0.07) 7.32 (0.1)
Baseline serum creatinine, mg % 1.40 (0.9) 1.38 (1.03) 1.41 (0.8)
Serum creatinine at 24 h 1.1 (0.59) 0.9 (0.4) 1.5 (0.9)
rSO2 brachioradialsis
Baseline rSO2, mean (SD) 62.9 (10.7) 68 (61–72) 46 (43–57)***
rSO2 at 24 h, mean (SD) 65.4 (12.3) 69 (60–76) 52 (41–57)***
Baseline rSO2 < 60, n (%) 14 (35) 7 (21.9) 7 (87.5)***
rSO2 < 60 at 24 h, n (%) 6 (15.8) 4 (12.5) 7 (87.5)***
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according to initial rSO2 variation with a higher mortality
rate in “no responders” (n = 3/7, 42.9 %) and “partially
responders” (n = 3/7, 42.9 %) patients than “responder pa-
tients” (n = 1/26, 3.8 %, p < 0.005) with an OR = 18.7, 95 %
CI 1.17–625.6 and a log rank = 5.99, p = 0.05 (Fig. 2). In
addition, we performed a Cox regression analysis to deter-
mine if rSO2 < 60 % was associated with mortality. The
regression analysis showed that “low” rSO2 at ICU admis-
sion (hazard ratio (HR) = 8.99; 95 % CI 1.05–76.8; p =
0.045) and “low” rSO2 at 24 h (HR = 13.18; 95 % CI 1.52–
113.6; p = 0.019) were variables independently associated
with mortality. In contrast, APACHE II score (HR = 1.09;
95 % CI 0.99–1.19; p = 0,052) was not associated with
mortality (Table 3).
Finally, the discriminatory ability of each variable for
ICU mortality was measured using the area under ROC
curves (AUC). The AUC showed consistent mortality
discrimination at baseline (0.84; 95 % CI 0.626–1.057,
p = 0.004) and at 24 h (0.86; 95 % CI 0.646–1.075, p = 0.002)
for rSO2 values, better than other resuscitation variables
(Table 4).
Discussion
The main finding of our study is that in a population of
patients with severe CAP, an early value of skeletal
muscle rSO2 <60 % was associated with a worse progno-
sis despite similar severity of illness, representing near
sixfold increase in the risk of death compared with pa-
tients with rSO2 ≥ 60 %. In addition, rSO2 variation
(from admission to 24 h) allowed distinguishing three
different types of responses to treatment which were
associated with different evolution. To the best of our
knowledge, our data is the first to report the relationship
between rSO2 alterations and CAP prognosis with this
NIRS device.
Table 1 Clinical characteristics, hemodynamic variables and biochemical data with simultaneous measurements of skeletal muscle
rSO2 of 40 patients included (Continued)
Therapy, mean (SD)
Norepinephrine at baseline μg/kg/min 0.35 (0.26) 0.40 (0.14) 0.29 (0.36)
Norepinephrine at 24 h, μg/kg/min 0.35 (0.29) 0.22 (0.28) 0.52 (0.23)*
Fluid balance at 24 h, mL 1650 (1350) 1470 (800) 2300 (2500)
ICU length of stay
Median IQR 25–75 % 18 (11–30) 18 (11–31) 24 (8–30)
SD standard deviation, IQR interquartile range, APACHE II Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment, ATS
American Thoracic Society, rSO2 regional oxygen saturation index
For survivors vs. non-survivors comparison *p = 0.01; **p < 0.05; ***p < 0.001
aOnly 11 patients
Fig. 1 Survival graph (Kaplan-Meier plot) for patients according baseline rSO2 cut-off values. ICU LOS intensive care unit length of stay (days), rSO2
regional oxygen saturation index
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Despite advances in diagnosis and antimicrobial therapy,
severe CAP remains an important cause of morbidity and
mortality, especially in patients requiring ICU admission
[1–6]. Unfortunately, it remains unknown whether spe-
cific clinical conditions or biomarkers can be used to iden-
tify patients with potential high risk of death.
Several risk factors that predict which patients will de-
velop moderate to severe CAP have been identified in a
small number of studies [1–3]. Our group [26] found
that a prompt oxygenation assessment in the emergency
department shortened the time taken to initiate anti-
biotic therapy and improved survival. Practice guidelines
based on severity assessment tools, such as the ATS
admission criteria or CURB-65 score, allow high-risk
patients to be identified and given specific treatment.
However, the prediction rule is derived from clinical data
and laboratory parameters which are time-consuming,
thereby limiting the clinical applications of predictive
outcomes [27, 28]. Several biomarkers have been pro-
posed to assess severity of illness and outcome. Inflam-
matory cytokines such as interleukin-6, procalcitonin,
albumin and C-reactive protein levels have also shown
to predict the severity of illness and 28-day mortality
[29, 30]. However, most of these factors merely reflect
individual coagulation and inflammation status and have
no therapeutic potential in themselves. Therefore,
Table 2 Levels of severity of illness and baseline resuscitation variables in 40 patients with severe community-acquired pneumonia
according to basal brachioradialis muscle rSO2
Variable rSO2 < 60 % (n = 14) rSO2≥ 60 % (n = 26) p value
APACHE II score , median (IQR 25–75) 18 (15–22) 15 (12–22) 0,26
SOFA score, median (IQR 25–75) 4,5 (3–5,5) 4 (3–5) 0,73
MAP (mmHg), median (IQR 25–75) 84 (69,7–93) 75 (71,7–94,7) 0,64
SL (mM/L), mean (SD) 4,2 (4,8) 2,3 (1,5) 0,17
BD, mean (SD) −1,7 (6,7) −4,4 (3,9) 0,11
Catecholamines (μg/kg/min), mean (SD) 0,39 (1,5) 0,32 (0,32) 0,66
Fluid balance at 24 h (mL), mean (SD) 2130 (2200) 1450 (759) 0.18
Need for MV, n (%) 8 (57) 13 (50) 0,58
ICU mortality rate, n (%) 7 (50) 1 (3,8) 0,001
APACHE II Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment, MAP medium arterial pressure, SL serum lactate, BD base
deficit, rSO2 regional oxygen saturation index, MV mechanical ventilation, IQR interquartile range, SD standard deviation
Fig. 2 Survival graph (Kaplan-Meier plot) for patients according to variation (0–24 h) of rSO2 with treatment. No responders: which showed no
improvement or a decrease in rSO2 value; Responders: patients which showed an improvement in rSO2 value to reach rSO2 of >60 % at 24 h
and; Partially responders: patients in which the rSO2 value improved but did not reach >60 % at 24 h; ICU LOS intensive care unit length of stay
(days), rSO2 regional oxygen saturation index
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identification of variables capable of not only predicting
outcomes but also providing a potential therapeutic tar-
get would be more useful in clinical applications.
Microvascular alterations are frequently observed in
patients with sepsis. In humans, several studies have
shown that severity of the alterations in microvascular
perfusion is associated with poor outcome [12–14]. A
crucial question is whether these microcirculatory alter-
ations merely reflect the severity of the disease or
contribute independently to mortality. Among the tools
available for tissue microcirculation/oxygenation assess-
ment, NIRS devices seem promising. It has been shown
in different life-threatening conditions that muscle skel-
etal oxygen saturation might characterize tissue hypo-
perfusion and effectiveness of therapy in trauma [20]
and septic shock [17–19, 21]. However, the relationship
between skeletal oxygen saturation with macrohemo-
dynamics variables is not entirely clear. Small-sized
trials showed that microvascular alterations were rela-
tively independent of MAP, CO and vasopressor agent
use [19, 31, 32]. In our study, no significant correl-
ation was observed between the values of NIRS and
classic hemodynamic variables. In contrast, other au-
thors observed a significant relationship between CO
and skeletal muscle oxygen saturation [20, 33]. In this
way, our data cannot be compared with that available in
the literature using other NIRS devices. Important tech-
nical differences should be considered before interpreting
and comparing data based on NIRS technology. In the
near-infrared range, oxyhaemoglobin (HbO2), deoxyhaea-
moglobin (Hb) and oxidized cytochrome oxidase (CytOx)
have characteristic absorption spectra. In order to derive
concentration changes simultaneously for Hb, HbO2 and
CytOx, values for absorption at four wavelengths of near
infrared are often used. The calculation used to solve the
modified Beer-Lambert equation at each of these wave-
lengths is known as an algorithm. Algorithms are different
for each device and also vary depending on the presence
of other chromophores and the precise values for the
absorption coefficients chosen [34–36]. Recent work has
applied different published algorithms to the same data
set and revealed striking differences in the calculated con-
centration changes [37, 38]. In addition, it is crucial to
know the differential pathlength factor (DPF) when inter-
preting NIRS data. DPF is the distance travelled by each
photon, and its value is derived from studies in healthy
adults [39]; it may vary in other situations and is also
wavelength-dependent. DPF may also change within the
same subject over a period of time if the state of the tissue
or tissue geometry alters [40]. Thus, probably, “normal”
and critically “abnormal” tissue oxygenation values should
be determined according to the critically ill patient popu-
lation and the NIRS device used.
Besides differences regarding technical characteristics
of each NIRS device, different values have been ob-
tained when measuring rSO2 in different muscles. Our
group found different values of rSO2 in brachioradialis
and deltoid muscles of septic patients, although in each
location “low” rSO2 values were associated with poor
outcome [18]. Other groups have found these differ-
ences between muscles [41].
Although our patients in shock had lower values of
rSO2 during the entire study period, we observed a non-
significant relationship between MAP, vasopressor dose
administered or SvO2 and rSO2. These findings may sug-
gest that these variables do not affect rSO2 significantly.
Classically, in septic shock, adequacy of perfusion for
oxygen demand is assessed by serum lactate and base
deficit levels [11, 15]. In the present study, serum lactate
and base deficit levels were not associated with poor out-
come. Skeletal muscle rSO2 may provide a more accurate
reflection of oxygen delivery because it represents the
balance between the oxygen supply to the capillaries
directly beneath the sensor and oxygen consumption at
that site independently of global hemodynamic state [17].
The rSO2 is indicative of oxygen extraction from haemo-
globin and in comparison with arterial oxygen saturation,
and possibly SvO2, it might provide a more accurate
picture of hypoxia [17]. In fact, according to present data,
Table 3 Results of cox regression analysis
Variable Hazard ratio 95 % CI p value
Presence of shock 1.01 0.09–11.15 0.98
Need of MV 29.8 0.01–4.2E 0.94
APACHE II 1.09 0.99–1.19 0.052
“low” rSO2 (admission) 8.99 1.05–76.8 0.045
“low” rSO2 (24 h) 13.18 1.52–113.6 0.019
MV mechanical ventilation, APACHE II Acute Physiology and Chronic Health
Evaluation, rSO2 regional oxygen saturation, CI confidence interval
Table 4 Area under ROC curve (AUROC). Discrimination for
mortality of rSO2 and hemodynamic variables and APACHE II
score
Variable AUROC 95 % CI p value
rSO2 baseline 0.84 0.626–1.057 0.004
24 h 0.86 0.646–1.075 0.002
Lactate baseline 0.57 0.334–0.820 0.51
24 h 0.69 0.434–0.951 0.10
BD baseline 0.44 0.200–0.680 0.61
24 h 0.70 0.477–0.927 0.08
MAP baseline 0.58 0.391–0.782 0.46
24 h 0.52 0.321–0.726 0.83
APACHE II 0.76 0.559–0.980 0.02
CI confidence interval, rSO2 regional oxygen saturation index, BD base deficit,
MAP medium arterial pressure, APACHE II Acute Physiology and Chronic
Health Evaluation
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the microcirculatory response to the treatment adminis-
tered might be evaluated by the variation of rSO2. Patients
with basal “low” rSO2 that respond appropriately to early
treatment (first 24 h) and normalize the rSO2 (≥60 %) pre-
sented an ICU evolution significantly better than patients
who despite improving rSO2 did not reach this cut-off.
The discriminatory ability for mortality was substan-
tially higher for rSO2 than serum lactate and base deficit
(except for 24 h). This suggests that skeletal muscle
rSO2 can detect early poor tissue oxygenation that re-
sults in serum lactate or base deficit elevation during
septic shock. Taking these into account, it is reasonable
to think that rSO2 emerges as an early indicator of poor
oxygenation with implications on prognosis. In addition,
Cox regression analysis showed that “low” rSO2 value,
both at ICU admission and at 24 h, was independently
associated with mortality.
Our study had several limitations. First, the sample
size was small in a single centre, which may account for
some lack of statistical significance. The small patient
population also prevented a subgroup analysis to further
examine the differences in the effects of rSO2 on clinical
outcomes according to some special clinical condition.
However, clear differences in rSO2 values were observed
between survivors and non-survivors. This suggests that
rSO2 gives early evidence of patients with severe CAP
who suffer oxygenation alterations with prognostic
implications. Second, we not have been able to calculate
the sample size to be included because there is no previ-
ous data with this population of patients and this NIRS
device. However, we calculate the statistical power of
our study which has been very high. Accepting a risk
alpha of 0.05 in a bilateral contrast with 26 subjects in
the first group (≥60 %) and 14 in the second (<60 %),
the power of the contrast of hypotheses is 94 % to
detect as a statistically significant difference that exists
between 3, 5 % in the first group and 50 % in the second
for mortality.
Third, NIRS does not directly measure microcircula-
tory flow. However, many studies [42, 43] have observed
that NIRS values correlated well with global and specific
organ perfusion parameters. In addition, NIRS signal is
limited to vessels that have a diameter <1 mm (arteri-
oles, capillaries and venules) and may be a useful tool
for non-invasive monitoring of microcirculation in septic
patients [13]. Fourth, we evaluated ICU mortality and
not longer-term mortality, but the latter may also be
influenced by other factors that are more related to the
underlying disease and comorbidities. Fifth, we only
included patients with CAP for which our data cannot
be translated to other populations of patients with
sepsis. Finally, we did not carry out a vascular occlusion
test (VOT). VOT might to improve and expand the pre-
dictive ability of rSO2 in several scenarios [19, 44, 45].
However, our findings showed a high discriminatory
power for absolute rSO2 values in accordance with our
previous findings [17].
Conclusions
Our findings suggest that forearm skeletal muscle rSO2 de-
termined at an early stage of severe community-acquired
pneumonia is likely to be associated with outcome. Future
studies are required to further substantiate our findings
and to confirm the potential benefits of assessing skeletal
muscle rSO2 on severe CAP.
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